Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPYD-guided Fluoropyrimidine Dosing
NCT07158164Phase 4Recruiting
- Sponsor
- Rutgers University
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluorouracil, capecitabine in colorectal cancer (CRC), breast cancer, head and neck cancer (HNC), gastrointestinal intraepithelial neoplasia (GIN), sponsored by Rutgers University. Started Aug 2025; status: recruiting.
02
Drugs
fluorouracilcapecitabine
03
Conditions
colorectal cancer (CRC)breast cancerhead and neck cancer (HNC)gastrointestinal intraepithelial neoplasia (GIN)
Beyond the preview
Go deeper on NCT07158164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158164.